Mark Levick
Alvotech was founded in 2013, with the clear mission to become a global leader in Biogenerics, defined as differentiated, high-quality, cost-controlled biosimilars. We have pursued this goal by creating a fully-integrated specialty company in control of every value adding development step from cell line development to commercial manufacturing of the product.
Our commitment
Our in-house development and manufacturing platform located at four sites across Europe drives timely development of a strong and differentiated portfolio, while our state-of-theart flexible manufacturing facility ensures high quality and cost-effective production. We are passionate about what we have created and our stated purpose of transforming access to life-altering therapies for patients across the globe. We believe in focus and specialization and each of our 400 professionals share our passion and pride to be part of this mission.
Through dedication and hard work, we will become a leading global biosimilar company. Our commitment to our partners is to be the best, most flexible supplier, with the capability to adapt to changing market demands. These elements are the key to Alvotech’s success.
We have created
In our short history, we have created a uniquely positioned biopharmaceutical company that focuses purely on the biosimilar market with complete vertical integration from early R&D to commercial manufacturing with subsidiaries in four European countries.
Our in house R&D platform drives the timely development of our strong pipeline and our state-of-the-art flexible biomanufacturing facility ensures high quality and cost effective production.
Our team
A great team of more than 400 professionals share our passion to be part of this journey. Through dedication and hard work we will become a leading global biosimilar company.
Our commitment to our partners is to be the best, most flexible supplier, with the capability to adapt to changing market demands. These elements are the key to Alvotech’s success.
